ConductScience.org, home

Paper7066166

Spironolactone dose-response relationships in healthy subjects.

McInnes GT and 3 others. Br J Clin Pharmacol, 1982. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Spironolactone dose-response relationships in healthy subjects. Papers, record 7066166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7066166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Spironolactone dose-response relationships in healthy subjects.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1982
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.55
iCite
Revised in PubMed
2019-05-12
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McInnes GTG T
2Perkins RMR M
3Shelton JRJ R
4Harrison IRI R

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ElectrolytesMajor topic
SpironolactoneMajor topic
Adult
Dose-Response Relationship, Drug
Double-Blind Method
Drug Interactions
Fludrocortisone
Humans
Male
Natriuresis
Potassium

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15025912High doses of spironolactone in the treatment of liver cirrhosis with ascites.Br J Clin Pract1972https://conductscience.org/library/papers/5025912PubMed
24853286Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.Eur J Clin Pharmacol1974https://conductscience.org/library/papers/4853286PubMed
31100306Relative potency of prorenoate and spironolactone in normal man.Clin Pharmacol Ther1975https://conductscience.org/library/papers/1100306PubMed
41261153Spironolactone. I. Disposition and metabolism.Clin Pharmacol Ther1976https://conductscience.org/library/papers/1261153PubMed
51261155Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.Clin Pharmacol Ther1976https://conductscience.org/library/papers/1261155PubMed
6780038Spironolactone and potassium canrenoate in normal man.Clin Pharmacol Ther1976https://conductscience.org/library/papers/780038PubMed
7183514Agonist and antimineralocorticoid activities of spirolactones.Am J Physiol1976https://conductscience.org/library/papers/183514PubMed
8318952Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension.Clin Pharmacol Ther1977https://conductscience.org/library/papers/318952PubMed
9858213Spironolactone and canrenoate-K: relative potency at steady state.Clin Pharmacol Ther1977https://conductscience.org/library/papers/858213PubMed
10356569Spironolactone.Am Heart J1978https://conductscience.org/library/papers/356569PubMed
117357793Activity of sulfur-containing intermediate metabolites of spironolactone.Clin Pharmacol Ther1980https://conductscience.org/library/papers/7357793PubMed
127214797Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7214797PubMed
137249505Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7249505PubMed
147332740Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.Br J Clin Pharmacol1981https://conductscience.org/library/papers/7332740PubMed
1613703392Aldosterone antagonists.N Y State J Med1961https://conductscience.org/library/papers/13703392PubMed
1713743603The effect of an aldosterone antagonist on the renal response to sodium restriction.Clin Sci1961https://conductscience.org/library/papers/13743603PubMed
1814408392Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone.Endocrinology1960https://conductscience.org/library/papers/14408392PubMed
1913887873The aldosterone blocking effects of spirolactones.Jpn J Pharmacol1962https://conductscience.org/library/papers/13887873PubMed
2013899372A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.J Pharmacol Exp Ther1962https://conductscience.org/library/papers/13899372PubMed
2113975085Human assay of electrolyte-active steroids and their antagonists.Clin Sci1962https://conductscience.org/library/papers/13975085PubMed

Download CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42752325Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia.Ann Med2026https://conductscience.org/library/papers/42752325PubMed
39402039Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study.Nat Commun2024https://conductscience.org/library/papers/39402039PubMed
39204148
Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of Spironolactone.
Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39204148PubMed
35776281A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone.J Pharmacokinet Pharmacodyn2022https://conductscience.org/library/papers/35776281PubMed
29785539The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale.Cardiol Ther2018https://conductscience.org/library/papers/29785539PubMed
28507171First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis.Hypertension2017https://conductscience.org/library/papers/28507171PubMed
24133446PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.Front Pharmacol2013https://conductscience.org/library/papers/24133446PubMed
23070570Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.Nat Rev Nephrol2012https://conductscience.org/library/papers/23070570PubMed
6386025Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6386025PubMed
3884320Diuretics. Clinical pharmacology and therapeutic use (Part II).Drugs1985https://conductscience.org/library/papers/3884320PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7066166

GET https://conductscience.org/api/papers/v1/7066166/authors